Clinical Trials Logo

Filter by:
NCT ID: NCT06233461 Recruiting - Crohn's Disease Clinical Trials

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

Start date: March 5, 2024
Phase: Phase 2
Study type: Interventional

Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. The purpose of this study is to evaluate the efficacy and safety of TAK-279 versus placebo in participants with moderately to severely active Crohn's disease (CD). The main aim of this study is to learn if the 3 different doses of TAK-279 reduce bowel inflammation and ulcers in the bowel compared to the placebo after 12 weeks of treatment. Another aim is to compare any medical problems that participants have when they take TAK-279 or placebo and how well the participants tolerate any problems. An endoscopy will be used to check the bowel for inflammation. The participants will be treated with TAK-279 for 52 weeks (1 year). During the study, participants will visit their study clinic 15 times.t

NCT ID: NCT06231082 Recruiting - Clinical trials for Liver Disease Parenchymal

Bloody or Well Done. How Would You Like Your Liver Biopsy, Sir?

LIMPID
Start date: May 6, 2024
Phase: N/A
Study type: Interventional

This is a randomized comparative trial between percutaneous liver biopsy and EUS FNB guided liver biopsy in patients with parenchymal liver disease. Studies so far have been shown that EUS FNB guided liver biopsy is non inferior to percutaneous liver biopsy in terms of efficacy, provided several conditions are met (type of needle, wet suction, actuations). În terms of safety, it may be that EUS FNB have an advantage, as needle diameter is slightly smaller, needle is inserted under better visualisation especially in patients with large subcutaneous fat tissue and the possibility of examining the needle tract and plugging it with needle content if needed ("the blood patch technique"). However, although severe, the incidence of liver bleeding is low, so a comparative trial with the hypothesis that EUS FNB has fewer liver bleedings than percutaneous techniques would have a very large sample size. A recent study found out that abdominal pain at 2 hours after procedure is predictive for liver bleeding. So we have design a randomized prospective trial assuming that EUS FNB guided liver biopsy has significantly less abdominal pain at 2 hours after procedure when compared to percutaneous route, using abdominal pain at 2 hours as a surrogate marker for risk of liver bleeding.

NCT ID: NCT06226142 Recruiting - Clinical trials for Tracheostomy Complication

The Ultrasound-guided vs Bronchoscopy-guided vs Ultrasound-bronchoscopy-guided Percutaneous Tracheostomy Trial

BRONCUS-PDT
Start date: January 17, 2024
Phase: N/A
Study type: Interventional

This trial (BRONCUS) is a randomized one designed to evaluate the overall safety of ultrasound guided compared to bronchoscopy guided compared to ultrasound-bronchoscopy guided percutaneous tracheostomy, in order to find out if universal standardization is required or customized approach can be sufficient.

NCT ID: NCT06224023 Recruiting - Cirrhosis, Liver Clinical Trials

Predictive Values of Presepsin Levels in ASciteS in Patients With Chronic Liver Failure

PASS
Start date: May 6, 2024
Phase:
Study type: Observational

The investigators aim to study the predictive value of presepsin in ascites in newly admitted patients with chronic liver failure.

NCT ID: NCT06221969 Recruiting - Type 2 Diabetes Clinical Trials

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

Start date: January 16, 2024
Phase: Phase 3
Study type: Interventional

This study will look at how well CagriSema helps people with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe CagriSema. CagriSema will be compared to a medicine called tirzepatide that doctors may prescribe in some countries. Participants will get either CagriSema or tirzepatide. Which treatment participant get is decided by chance like flipping a coin. Participant will have an equal chance of receiving either drug. For each participant, the study will last for up to one and a half years.

NCT ID: NCT06220604 Recruiting - Plaque Psoriasis Clinical Trials

A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)

Start date: March 9, 2024
Phase: Phase 3
Study type: Interventional

The purpose of the study is to evaluate how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deucravacitinib.

NCT ID: NCT06220175 Recruiting - Clinical trials for Upper Gastrointestinal Endoscopy

Pharynx Analgesia Before Upper Gastrointestinal Endoscopy

PHRASE
Start date: May 6, 2024
Phase: N/A
Study type: Interventional

This is a comparative study on patient and endoscopist experience during upper gastrointestinal endoscopy with NSAIDs (flurbiprofen) topical analgesia versus xilocaine spray topical anesthesia of the pharynx, before procedure.

NCT ID: NCT06220149 Recruiting - Bleeding Clinical Trials

Post Polypectomy Bleeding. Que Sera, Sera? Whatever Will be, Will be?

FILLIP
Start date: May 6, 2024
Phase:
Study type: Observational

Patients with colorectal polyps removed endoscopically (polypectomy, endoscopic mucosal resection, underwater endoscopic mucosal resection, endoscopic submucosal dissection) may experience delayed post polypectomy bleeding. The incidence is about one in 40 cases. There are risks factors for this complication, depending on the polyp type, patient demographics and co-morbidities and polypectomy technique. There are meta-analysis and nomograms for risk prediction available. We will try to predict delayed post polypectomy bleeding by using FIT (fecal immunochemical test), with a cut-off adapted to detect post polypectomy bleeding, administered daily for 2 weeks after polypectomy.

NCT ID: NCT06218537 Recruiting - Clinical trials for Upper Gastrointestinal Endoscopy

The Role of oAncreatic Enzyme ReplAcement Therapy (PERT) on Mucosal Visibility Before Upper GI Endoscopy

AERATE
Start date: May 6, 2024
Phase: N/A
Study type: Interventional

The investigators aim to establish wether the administration of pancreatic enzyme replacement therapy (PERT) improves visibility of the mucosa during upper gastrointestinal endoscopy.

NCT ID: NCT06217744 Recruiting - Clinical trials for Mental Health Wellness 1

Mental Health Literacy and Academic Performance

MHLAP
Start date: May 10, 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to test the effectiveness of an intervention designed to promote mental health literacy in adolescents. The main questions it aims to answer are: 1. Whether this intervention can have an impact on mental health 2. Whether this intervention can have an impact on fostering academic performance, particularly in disadvantaged students (i.e., academic resilience) 3. Whether this intervention will have differential effectiveness as a function of the delivery format (psychoeducational materials only versus blended) Participants will receive either an online, automated intervention consisting of psychoeducational materials delivered at predetermined intervals (automated), or the same but with the addition of synchronous or asynchronous psychoeducational sessions held by a licensed psychologist (i.e., blended). These two conditions will also be compared to a Waitlist, to test if the interventions perform better than no treatment.